샘플 요청 목록

 카트 문의
시장보고서
상품코드
1798907

세계의 HER2 유방암 검사 시장

HER2 Breast Cancer Tests
발행일: | 리서치사: Market Glass, Inc. (Formerly Global Industry Analysts, Inc.) | 페이지 정보: 영문 268 Pages | 배송안내 : 1-2일 (영업일 기준)

    
    
    



※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

HER2 유방암 검사 세계 시장은 2030년까지 5억 2,950만 달러에 달할 전망

2024년에 3억 9,440만 달러로 추정되는 HER2 유방암 검사 세계 시장은 2030년에는 5억 2,950만 달러에 달하고, 분석 기간인 2024-2030년 CAGR은 5.0%로 성장할 것으로 예측됩니다. 이 보고서에서 분석한 부문 중 하나인 면역조직화학 검사는 CAGR 4.0%를 기록하며 분석 기간 종료시에는 3억 3,130만 달러에 달할 것으로 예측됩니다. 형광/발색 In-Situ 하이브리다이제이션 검사 분야의 성장률은 분석 기간 동안 CAGR 6.8%로 추정됩니다.

미국 시장은 1억 740만 달러로 추정, 중국은 CAGR 7.8%로 성장 예측

미국의 HER2 유방암 검사 시장은 2024년에 1억 740만 달러로 추정됩니다. 세계 2위 경제 대국인 중국은 2030년까지 1억 410만 달러의 시장 규모에 달할 것으로 예측되며, 분석 기간인 2024-2030년 CAGR은 7.8%를 기록할 것으로 예상됩니다. 기타 주목할 만한 지역별 시장으로는 일본과 캐나다가 있고, 분석 기간 동안 CAGR은 각각 2.5%와 5.0%로 예측됩니다. 유럽에서는 독일이 CAGR 3.2%로 성장할 것으로 예측됩니다.

세계의 HER2 유방암 검사 시장 - 주요 동향과 촉진요인 정리

HER2 유방암 검사가 현대 종양학에서 필수적인 이유는 무엇인가?

HER2(Human Epidermal Growth Factor Receptor 2) 유방암 검사는 유방암 조직에서 HER2 유전자의 과발현 또는 증폭을 판단하기 위해 사용되는 진단 절차입니다. HER2 양성 암은 일반적으로 증식이 빠르고 표적치료에 대한 반응도 다르기 때문에 이러한 검사는 치료 방침을 결정하는 데 매우 중요합니다. 정확한 식별을 통해 트라스투주맙, 퍼투주맙 등 HER2 활성을 특이적으로 억제하여 생존 예후를 개선하는 치료법을 선택할 수 있습니다.

검사는 일반적으로 생검 또는 수술 조직 샘플을 이용한 면역조직화학(IHC) 또는 in situ hybridization(ISH) 기술을 통해 이루어집니다. 최근 진단 정확도를 높이기 위해 첨단 분석법, 디지털 병리학적 솔루션, 동반진단 약품이 등장하고 있습니다. HER2 검사는 현재 종양센터의 유방암 진단 루틴의 일부로 자리 잡았으며, 이는 고품질의 신뢰할 수 있는 진단 플랫폼에 대한 수요 증가에 기여하고 있습니다.

어떤 진단 혁신이 검사의 정확성과 보급에 영향을 미치고 있는가?

기술의 발전으로 HER2 검사의 민감도, 재현성, 해석 가능성은 향상되고 있습니다. IHC 검사는 강화된 항체, 자동 염색 시스템, 표준화된 채점 알고리즘을 통해 진화해 왔습니다. 듀얼 프로브 ISH 검사는 모호한 경우 확신을 주고, 경계 부위의 HER2 발현을 해결하는 데 도움이 됩니다. 형광 ISH(FISH) 및 발색 ISH(CISH)는 세포 수준에서 유전자 증폭을 확인하는 데 널리 사용되고 있습니다.

새로운 플랫폼은 진단 워크플로우를 강화하기 위해 디지털 영상, AI 지원 병리, 멀티플렉스 검사 기능을 통합하여 진단 워크플로우를 강화합니다. 일부 HER2 분석은 여러 바이오마커를 동시에 평가하는 광범위한 유전체 프로파일링 검사의 일부로 개발되고 있습니다. 특히 HER2를 표적으로 하는 치료가 위암, 대장암 등 다른 암종으로 확대되면서 표적 치료제와 함께 공동 개발된 동반진단 검사도 인기를 끌고 있습니다.

검사량은 어디에서 증가하고 있으며, 어떤 시설이 보급을 주도하고 있는가?

유방암 발병률의 증가와 종양학에서 맞춤형 의료의 도입이 확대됨에 따라 전 세계적으로 검사량이 증가하고 있습니다. 병원, 암전문센터, 표준검사실이 주요 검사시설입니다. 고소득 국가에서는 HER2 검사가 유방암 검진의 표준 검사 항목이며, 중산층 지역에서는 병리학적 인프라와 치료 접근성 향상으로 인해 검사에 대한 관심이 높아지고 있습니다.

북미와 유럽은 진단 가이드라인과 상환제도가 확립된 성숙한 시장입니다. 아시아태평양은 유방암에 대한 인식 제고, 표적 치료 접근성 확대, 정부의 암 진단약 지원 정책 등으로 인해 빠르게 성장하고 있습니다. 민관 협력과 전국적인 암 검진 프로그램 개발은 검진 보급을 더욱 가속화하고 있습니다.

HER2 유방암 검사 시장의 성장 원동력은?

HER2 유방암 검사 시장의 성장은 전 세계 유방암 발병률 증가, HER2 표적 치료제 사용 증가, 진단 정확도의 지속적인 향상 등 여러 요인에 의해 이루어지고 있습니다. 염색 시약, 자동화 시스템, AI를 탑재한 병리검사 도구의 발전으로 HER2 검사의 정확성과 확장성이 높아지고 있습니다.

암 전문병원, 병리검사실, HER2 표적 신약의 동반진단에 대한 최종 용도 확대가 시장의 관련성을 높이고 있습니다. 유방암 이외의 종양 유형에서 HER2 검사의 규제 승인과 멀티플렉스 바이오마커 패널의 채택이 증가함에 따라 그 적용 범위가 확대되고 있습니다. 정밀의료가 종양 치료의 중심이 됨에 따라, 신뢰할 수 있는 고처리량 HER2 검사 솔루션에 대한 수요는 꾸준히 증가할 것으로 예상됩니다.

부문

검사 유형(면역조직화학 검사, 형광/발색 In-Situ 하이브리다이제이션 검사), 최종사용자(병원 최종사용자, 진단 실험실 최종사용자)

조사 대상 기업 사례

  • Abbott Laboratories
  • Abnova Corporation
  • Agilent Technologies
  • Bio-Genex Laboratories
  • Beckman Coulter(Danaher)
  • Becton, Dickinson and Company(BD)
  • EKF Diagnostics
  • Hologic, Inc.
  • Leica Biosystems(Danaher)
  • Meridian Bioscience
  • Olympus Corporation
  • Oxford Gene Technology(Sysmex)
  • QIAGEN N.V.
  • REVEAL Genomics S.L.
  • Roche Diagnostics(F. Hoffmann-La Roche)
  • Thermo Fisher Scientific
  • Veracyte, Inc.
  • NeoGenomics Laboratories, Inc.
  • Empire Genomics/Biocare Medical
  • Applied Spectral Imaging

AI 통합

우리는 검증된 전문가 컨텐츠와 AI 툴을 통해 시장 정보와 경쟁 정보를 혁신하고 있습니다.

Global Industry Analysts는 LLM 및 업계 고유의 SLM을 조회하는 일반적인 규범을 따르는 대신 비디오 기록, 블로그, 검색 엔진 조사, 방대한 양의 기업, 제품/서비스, 시장 데이터 등 세계 전문가로부터 수집한 컨텐츠 리포지토리를 구축했습니다.

관세 영향 계수

Global Industry Analysts는 본사 소재지, 제조거점, 수출입(완제품 및 OEM)을 기준으로 기업의 경쟁력 변화를 예측하고 있습니다. 이러한 복잡하고 다면적인 시장 역학은 매출원가(COGS) 증가, 수익성 하락, 공급망 재편 등 미시적, 거시적 시장 역학 중에서도 특히 경쟁사들에게 영향을 미칠 것으로 예상됩니다.

목차

제1장 조사 방법

제2장 주요 요약

  • 시장 개요
  • 주요 기업
  • 시장 동향과 촉진요인
  • 세계 시장 전망

제3장 시장 분석

  • 미국
  • 캐나다
  • 일본
  • 중국
  • 유럽
  • 프랑스
  • 독일
  • 이탈리아
  • 영국
  • 스페인
  • 러시아
  • 기타 유럽
  • 아시아태평양
  • 호주
  • 인도
  • 한국
  • 기타 아시아태평양
  • 라틴아메리카
  • 아르헨티나
  • 브라질
  • 멕시코
  • 기타 라틴아메리카
  • 중동
  • 이란
  • 이스라엘
  • 사우디아라비아
  • 아랍에미리트
  • 기타 중동
  • 아프리카

제4장 경쟁

KSM 25.09.03

Global HER2 Breast Cancer Tests Market to Reach US$529.5 Million by 2030

The global market for HER2 Breast Cancer Tests estimated at US$394.4 Million in the year 2024, is expected to reach US$529.5 Million by 2030, growing at a CAGR of 5.0% over the analysis period 2024-2030. Immunohistochemistry Test, one of the segments analyzed in the report, is expected to record a 4.0% CAGR and reach US$331.3 Million by the end of the analysis period. Growth in the Fluorescence / Chromogenic In-Situ Hybridization Test segment is estimated at 6.8% CAGR over the analysis period.

The U.S. Market is Estimated at US$107.4 Million While China is Forecast to Grow at 7.8% CAGR

The HER2 Breast Cancer Tests market in the U.S. is estimated at US$107.4 Million in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$104.1 Million by the year 2030 trailing a CAGR of 7.8% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 2.5% and 5.0% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 3.2% CAGR.

Global HER2 Breast Cancer Tests Market - Key Trends & Drivers Summarized

Why Are HER2 Breast Cancer Tests Essential in Modern Oncology?

HER2 (Human Epidermal Growth Factor Receptor 2) breast cancer tests are diagnostic procedures used to determine the overexpression or amplification of the HER2 gene in breast cancer tissue. These tests are critical in guiding treatment decisions, as HER2-positive cancers typically grow faster and respond differently to targeted therapies. Accurate identification allows for the selection of therapies such as trastuzumab or pertuzumab, which specifically inhibit HER2 activity and improve survival outcomes.

Testing is typically performed using immunohistochemistry (IHC) or in situ hybridization (ISH) techniques on biopsy or surgical tissue samples. In recent years, advanced assays, digital pathology solutions, and companion diagnostics have emerged to improve diagnostic precision. HER2 testing is now a routine part of breast cancer diagnosis in oncology centers, contributing to the growing demand for high-quality and reliable diagnostic platforms.

What Diagnostic Innovations Are Influencing Test Accuracy and Adoption?

Technological advancements have improved HER2 test sensitivity, reproducibility, and interpretability. IHC tests have evolved with enhanced antibodies, automated staining systems, and standardized scoring algorithms. Dual-probe ISH tests provide confirmation in ambiguous cases, helping resolve borderline HER2 expressions. Fluorescence ISH (FISH) and chromogenic ISH (CISH) remain widely used for confirming gene amplification at the cellular level.

Emerging platforms are integrating digital imaging, AI-assisted pathology, and multiplex testing capabilities to enhance diagnostic workflows. Some HER2 assays are now being developed as part of broader genomic profiling tests that assess multiple biomarkers simultaneously. Companion diagnostic tests co-developed with targeted drugs are also gaining traction, especially as HER2-targeted treatments expand into other tumor types like gastric and colorectal cancers.

Where Is Testing Volume Increasing, and Which Institutions Are Driving Uptake?

Testing volumes are rising globally due to increasing breast cancer incidence and the growing adoption of personalized medicine in oncology. Hospitals, cancer specialty centers, and reference laboratories are key testing sites. In high-income countries, HER2 testing is a standard part of breast cancer workups, while in middle-income regions, uptake is increasing with improvements in pathology infrastructure and treatment access.

North America and Europe are mature markets with well-established diagnostic guidelines and reimbursement systems. Asia Pacific is witnessing rapid growth due to rising breast cancer awareness, expanding access to targeted therapies, and government initiatives supporting oncology diagnostics. The development of public-private partnerships and national cancer screening programs is further accelerating testing penetration.

What Is Driving Growth in the HER2 Breast Cancer Tests Market?

Growth in the HER2 breast cancer tests market is driven by several factors including rising global breast cancer incidence, increased use of HER2-targeted therapies, and ongoing improvements in diagnostic precision. Advances in staining reagents, automation systems, and AI-powered pathology tools are making HER2 testing more accurate and scalable.

End-use expansion in oncology hospitals, pathology labs, and companion diagnostics for new HER2-targeted drugs is boosting market relevance. Regulatory approvals for HER2 testing in tumor types beyond breast cancer and increased adoption of multiplex biomarker panels are broadening application scope. As precision medicine becomes central to oncology care, demand for reliable, high-throughput HER2 testing solutions is expected to grow steadily.

SCOPE OF STUDY:

The report analyzes the HER2 Breast Cancer Tests market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Test Type (Immunohistochemistry Test, Fluorescence / Chromogenic In-Situ Hybridization Test); End-User (Hospitals End-User, Diagnostic Laboratories End-User)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 37 Featured) -

  • Abbott Laboratories
  • Abnova Corporation
  • Agilent Technologies
  • Bio-Genex Laboratories
  • Beckman Coulter (Danaher)
  • Becton, Dickinson and Company (BD)
  • EKF Diagnostics
  • Hologic, Inc.
  • Leica Biosystems (Danaher)
  • Meridian Bioscience
  • Olympus Corporation
  • Oxford Gene Technology (Sysmex)
  • QIAGEN N.V.
  • REVEAL Genomics S.L.
  • Roche Diagnostics (F. Hoffmann-La Roche)
  • Thermo Fisher Scientific
  • Veracyte, Inc.
  • NeoGenomics Laboratories, Inc.
  • Empire Genomics / Biocare Medical
  • Applied Spectral Imaging

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • World Market Trajectories
    • Tariff Impact on Global Supply Chain Patterns
    • HER2 Breast Cancer Tests - Global Key Competitors Percentage Market Share in 2025 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Rising Global Incidence of Breast Cancer Drives Consistent Demand for HER2 Status Testing in Oncology Diagnostics
    • Increased Adoption of Targeted Therapy Approaches Strengthens Business Case for Routine HER2 Screening
    • Growing Use of HER2 Tests in Treatment Stratification Spurs Integration into First-Line Diagnostic Protocols
    • Expansion of Companion Diagnostics for HER2-Targeted Drugs Throws Spotlight on Precision Testing Technologies
    • Regulatory Approvals for HER2-Positive Therapies Boost Clinical Need for Accurate and Standardized HER2 Testing
    • Adoption of FISH, IHC, and Dual ISH Techniques Enables Multi-Modality Testing Options in Oncology Labs
    • Rising Healthcare Access and Diagnostic Infrastructure in Emerging Markets Enhances HER2 Test Availability
    • Growth in Breast Cancer Screening Programs Supports Early Detection and HER2-Based Prognostic Evaluation
    • Increasing Use of Biopsy and Cytology Samples in HER2 Testing Expands Test Adoption Across Specimen Types
    • Integration of HER2 Testing in Comprehensive Genomic Panels Propels Use in Broader Molecular Oncology Workflows
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World HER2 Breast Cancer Tests Market Analysis of Annual Sales in US$ Thousand for Years 2014 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for HER2 Breast Cancer Tests by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 3: World Historic Review for HER2 Breast Cancer Tests by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 4: World 16-Year Perspective for HER2 Breast Cancer Tests by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2014, 2025 & 2030
    • TABLE 5: World Recent Past, Current & Future Analysis for Immunohistochemistry Test by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 6: World Historic Review for Immunohistochemistry Test by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 7: World 16-Year Perspective for Immunohistochemistry Test by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Fluorescence / Chromogenic In-Situ Hybridization Test by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 9: World Historic Review for Fluorescence / Chromogenic In-Situ Hybridization Test by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 10: World 16-Year Perspective for Fluorescence / Chromogenic In-Situ Hybridization Test by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 11: World Recent Past, Current & Future Analysis for Hospitals End-User by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 12: World Historic Review for Hospitals End-User by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 13: World 16-Year Perspective for Hospitals End-User by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for Diagnostic Laboratories End-User by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 15: World Historic Review for Diagnostic Laboratories End-User by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 16: World 16-Year Perspective for Diagnostic Laboratories End-User by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • HER2 Breast Cancer Tests Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
    • TABLE 17: USA Recent Past, Current & Future Analysis for HER2 Breast Cancer Tests by Test Type - Immunohistochemistry Test and Fluorescence / Chromogenic In-Situ Hybridization Test - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 18: USA Historic Review for HER2 Breast Cancer Tests by Test Type - Immunohistochemistry Test and Fluorescence / Chromogenic In-Situ Hybridization Test Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 19: USA 16-Year Perspective for HER2 Breast Cancer Tests by Test Type - Percentage Breakdown of Value Sales for Immunohistochemistry Test and Fluorescence / Chromogenic In-Situ Hybridization Test for the Years 2014, 2025 & 2030
    • TABLE 20: USA Recent Past, Current & Future Analysis for HER2 Breast Cancer Tests by End-user - Hospitals End-User and Diagnostic Laboratories End-User - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 21: USA Historic Review for HER2 Breast Cancer Tests by End-user - Hospitals End-User and Diagnostic Laboratories End-User Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 22: USA 16-Year Perspective for HER2 Breast Cancer Tests by End-user - Percentage Breakdown of Value Sales for Hospitals End-User and Diagnostic Laboratories End-User for the Years 2014, 2025 & 2030
  • CANADA
    • TABLE 23: Canada Recent Past, Current & Future Analysis for HER2 Breast Cancer Tests by Test Type - Immunohistochemistry Test and Fluorescence / Chromogenic In-Situ Hybridization Test - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 24: Canada Historic Review for HER2 Breast Cancer Tests by Test Type - Immunohistochemistry Test and Fluorescence / Chromogenic In-Situ Hybridization Test Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 25: Canada 16-Year Perspective for HER2 Breast Cancer Tests by Test Type - Percentage Breakdown of Value Sales for Immunohistochemistry Test and Fluorescence / Chromogenic In-Situ Hybridization Test for the Years 2014, 2025 & 2030
    • TABLE 26: Canada Recent Past, Current & Future Analysis for HER2 Breast Cancer Tests by End-user - Hospitals End-User and Diagnostic Laboratories End-User - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 27: Canada Historic Review for HER2 Breast Cancer Tests by End-user - Hospitals End-User and Diagnostic Laboratories End-User Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 28: Canada 16-Year Perspective for HER2 Breast Cancer Tests by End-user - Percentage Breakdown of Value Sales for Hospitals End-User and Diagnostic Laboratories End-User for the Years 2014, 2025 & 2030
  • JAPAN
    • HER2 Breast Cancer Tests Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
    • TABLE 29: Japan Recent Past, Current & Future Analysis for HER2 Breast Cancer Tests by Test Type - Immunohistochemistry Test and Fluorescence / Chromogenic In-Situ Hybridization Test - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 30: Japan Historic Review for HER2 Breast Cancer Tests by Test Type - Immunohistochemistry Test and Fluorescence / Chromogenic In-Situ Hybridization Test Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 31: Japan 16-Year Perspective for HER2 Breast Cancer Tests by Test Type - Percentage Breakdown of Value Sales for Immunohistochemistry Test and Fluorescence / Chromogenic In-Situ Hybridization Test for the Years 2014, 2025 & 2030
    • TABLE 32: Japan Recent Past, Current & Future Analysis for HER2 Breast Cancer Tests by End-user - Hospitals End-User and Diagnostic Laboratories End-User - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 33: Japan Historic Review for HER2 Breast Cancer Tests by End-user - Hospitals End-User and Diagnostic Laboratories End-User Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 34: Japan 16-Year Perspective for HER2 Breast Cancer Tests by End-user - Percentage Breakdown of Value Sales for Hospitals End-User and Diagnostic Laboratories End-User for the Years 2014, 2025 & 2030
  • CHINA
    • HER2 Breast Cancer Tests Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
    • TABLE 35: China Recent Past, Current & Future Analysis for HER2 Breast Cancer Tests by Test Type - Immunohistochemistry Test and Fluorescence / Chromogenic In-Situ Hybridization Test - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 36: China Historic Review for HER2 Breast Cancer Tests by Test Type - Immunohistochemistry Test and Fluorescence / Chromogenic In-Situ Hybridization Test Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 37: China 16-Year Perspective for HER2 Breast Cancer Tests by Test Type - Percentage Breakdown of Value Sales for Immunohistochemistry Test and Fluorescence / Chromogenic In-Situ Hybridization Test for the Years 2014, 2025 & 2030
    • TABLE 38: China Recent Past, Current & Future Analysis for HER2 Breast Cancer Tests by End-user - Hospitals End-User and Diagnostic Laboratories End-User - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 39: China Historic Review for HER2 Breast Cancer Tests by End-user - Hospitals End-User and Diagnostic Laboratories End-User Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 40: China 16-Year Perspective for HER2 Breast Cancer Tests by End-user - Percentage Breakdown of Value Sales for Hospitals End-User and Diagnostic Laboratories End-User for the Years 2014, 2025 & 2030
  • EUROPE
    • HER2 Breast Cancer Tests Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
    • TABLE 41: Europe Recent Past, Current & Future Analysis for HER2 Breast Cancer Tests by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 42: Europe Historic Review for HER2 Breast Cancer Tests by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 43: Europe 16-Year Perspective for HER2 Breast Cancer Tests by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2014, 2025 & 2030
    • TABLE 44: Europe Recent Past, Current & Future Analysis for HER2 Breast Cancer Tests by Test Type - Immunohistochemistry Test and Fluorescence / Chromogenic In-Situ Hybridization Test - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 45: Europe Historic Review for HER2 Breast Cancer Tests by Test Type - Immunohistochemistry Test and Fluorescence / Chromogenic In-Situ Hybridization Test Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 46: Europe 16-Year Perspective for HER2 Breast Cancer Tests by Test Type - Percentage Breakdown of Value Sales for Immunohistochemistry Test and Fluorescence / Chromogenic In-Situ Hybridization Test for the Years 2014, 2025 & 2030
    • TABLE 47: Europe Recent Past, Current & Future Analysis for HER2 Breast Cancer Tests by End-user - Hospitals End-User and Diagnostic Laboratories End-User - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 48: Europe Historic Review for HER2 Breast Cancer Tests by End-user - Hospitals End-User and Diagnostic Laboratories End-User Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 49: Europe 16-Year Perspective for HER2 Breast Cancer Tests by End-user - Percentage Breakdown of Value Sales for Hospitals End-User and Diagnostic Laboratories End-User for the Years 2014, 2025 & 2030
  • FRANCE
    • HER2 Breast Cancer Tests Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
    • TABLE 50: France Recent Past, Current & Future Analysis for HER2 Breast Cancer Tests by Test Type - Immunohistochemistry Test and Fluorescence / Chromogenic In-Situ Hybridization Test - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 51: France Historic Review for HER2 Breast Cancer Tests by Test Type - Immunohistochemistry Test and Fluorescence / Chromogenic In-Situ Hybridization Test Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 52: France 16-Year Perspective for HER2 Breast Cancer Tests by Test Type - Percentage Breakdown of Value Sales for Immunohistochemistry Test and Fluorescence / Chromogenic In-Situ Hybridization Test for the Years 2014, 2025 & 2030
    • TABLE 53: France Recent Past, Current & Future Analysis for HER2 Breast Cancer Tests by End-user - Hospitals End-User and Diagnostic Laboratories End-User - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 54: France Historic Review for HER2 Breast Cancer Tests by End-user - Hospitals End-User and Diagnostic Laboratories End-User Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 55: France 16-Year Perspective for HER2 Breast Cancer Tests by End-user - Percentage Breakdown of Value Sales for Hospitals End-User and Diagnostic Laboratories End-User for the Years 2014, 2025 & 2030
  • GERMANY
    • HER2 Breast Cancer Tests Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
    • TABLE 56: Germany Recent Past, Current & Future Analysis for HER2 Breast Cancer Tests by Test Type - Immunohistochemistry Test and Fluorescence / Chromogenic In-Situ Hybridization Test - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 57: Germany Historic Review for HER2 Breast Cancer Tests by Test Type - Immunohistochemistry Test and Fluorescence / Chromogenic In-Situ Hybridization Test Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 58: Germany 16-Year Perspective for HER2 Breast Cancer Tests by Test Type - Percentage Breakdown of Value Sales for Immunohistochemistry Test and Fluorescence / Chromogenic In-Situ Hybridization Test for the Years 2014, 2025 & 2030
    • TABLE 59: Germany Recent Past, Current & Future Analysis for HER2 Breast Cancer Tests by End-user - Hospitals End-User and Diagnostic Laboratories End-User - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 60: Germany Historic Review for HER2 Breast Cancer Tests by End-user - Hospitals End-User and Diagnostic Laboratories End-User Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 61: Germany 16-Year Perspective for HER2 Breast Cancer Tests by End-user - Percentage Breakdown of Value Sales for Hospitals End-User and Diagnostic Laboratories End-User for the Years 2014, 2025 & 2030
  • ITALY
    • TABLE 62: Italy Recent Past, Current & Future Analysis for HER2 Breast Cancer Tests by Test Type - Immunohistochemistry Test and Fluorescence / Chromogenic In-Situ Hybridization Test - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 63: Italy Historic Review for HER2 Breast Cancer Tests by Test Type - Immunohistochemistry Test and Fluorescence / Chromogenic In-Situ Hybridization Test Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 64: Italy 16-Year Perspective for HER2 Breast Cancer Tests by Test Type - Percentage Breakdown of Value Sales for Immunohistochemistry Test and Fluorescence / Chromogenic In-Situ Hybridization Test for the Years 2014, 2025 & 2030
    • TABLE 65: Italy Recent Past, Current & Future Analysis for HER2 Breast Cancer Tests by End-user - Hospitals End-User and Diagnostic Laboratories End-User - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 66: Italy Historic Review for HER2 Breast Cancer Tests by End-user - Hospitals End-User and Diagnostic Laboratories End-User Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 67: Italy 16-Year Perspective for HER2 Breast Cancer Tests by End-user - Percentage Breakdown of Value Sales for Hospitals End-User and Diagnostic Laboratories End-User for the Years 2014, 2025 & 2030
  • UNITED KINGDOM
    • HER2 Breast Cancer Tests Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
    • TABLE 68: UK Recent Past, Current & Future Analysis for HER2 Breast Cancer Tests by Test Type - Immunohistochemistry Test and Fluorescence / Chromogenic In-Situ Hybridization Test - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 69: UK Historic Review for HER2 Breast Cancer Tests by Test Type - Immunohistochemistry Test and Fluorescence / Chromogenic In-Situ Hybridization Test Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 70: UK 16-Year Perspective for HER2 Breast Cancer Tests by Test Type - Percentage Breakdown of Value Sales for Immunohistochemistry Test and Fluorescence / Chromogenic In-Situ Hybridization Test for the Years 2014, 2025 & 2030
    • TABLE 71: UK Recent Past, Current & Future Analysis for HER2 Breast Cancer Tests by End-user - Hospitals End-User and Diagnostic Laboratories End-User - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 72: UK Historic Review for HER2 Breast Cancer Tests by End-user - Hospitals End-User and Diagnostic Laboratories End-User Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 73: UK 16-Year Perspective for HER2 Breast Cancer Tests by End-user - Percentage Breakdown of Value Sales for Hospitals End-User and Diagnostic Laboratories End-User for the Years 2014, 2025 & 2030
  • SPAIN
    • TABLE 74: Spain Recent Past, Current & Future Analysis for HER2 Breast Cancer Tests by Test Type - Immunohistochemistry Test and Fluorescence / Chromogenic In-Situ Hybridization Test - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 75: Spain Historic Review for HER2 Breast Cancer Tests by Test Type - Immunohistochemistry Test and Fluorescence / Chromogenic In-Situ Hybridization Test Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 76: Spain 16-Year Perspective for HER2 Breast Cancer Tests by Test Type - Percentage Breakdown of Value Sales for Immunohistochemistry Test and Fluorescence / Chromogenic In-Situ Hybridization Test for the Years 2014, 2025 & 2030
    • TABLE 77: Spain Recent Past, Current & Future Analysis for HER2 Breast Cancer Tests by End-user - Hospitals End-User and Diagnostic Laboratories End-User - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 78: Spain Historic Review for HER2 Breast Cancer Tests by End-user - Hospitals End-User and Diagnostic Laboratories End-User Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 79: Spain 16-Year Perspective for HER2 Breast Cancer Tests by End-user - Percentage Breakdown of Value Sales for Hospitals End-User and Diagnostic Laboratories End-User for the Years 2014, 2025 & 2030
  • RUSSIA
    • TABLE 80: Russia Recent Past, Current & Future Analysis for HER2 Breast Cancer Tests by Test Type - Immunohistochemistry Test and Fluorescence / Chromogenic In-Situ Hybridization Test - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 81: Russia Historic Review for HER2 Breast Cancer Tests by Test Type - Immunohistochemistry Test and Fluorescence / Chromogenic In-Situ Hybridization Test Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 82: Russia 16-Year Perspective for HER2 Breast Cancer Tests by Test Type - Percentage Breakdown of Value Sales for Immunohistochemistry Test and Fluorescence / Chromogenic In-Situ Hybridization Test for the Years 2014, 2025 & 2030
    • TABLE 83: Russia Recent Past, Current & Future Analysis for HER2 Breast Cancer Tests by End-user - Hospitals End-User and Diagnostic Laboratories End-User - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 84: Russia Historic Review for HER2 Breast Cancer Tests by End-user - Hospitals End-User and Diagnostic Laboratories End-User Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 85: Russia 16-Year Perspective for HER2 Breast Cancer Tests by End-user - Percentage Breakdown of Value Sales for Hospitals End-User and Diagnostic Laboratories End-User for the Years 2014, 2025 & 2030
  • REST OF EUROPE
    • TABLE 86: Rest of Europe Recent Past, Current & Future Analysis for HER2 Breast Cancer Tests by Test Type - Immunohistochemistry Test and Fluorescence / Chromogenic In-Situ Hybridization Test - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 87: Rest of Europe Historic Review for HER2 Breast Cancer Tests by Test Type - Immunohistochemistry Test and Fluorescence / Chromogenic In-Situ Hybridization Test Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 88: Rest of Europe 16-Year Perspective for HER2 Breast Cancer Tests by Test Type - Percentage Breakdown of Value Sales for Immunohistochemistry Test and Fluorescence / Chromogenic In-Situ Hybridization Test for the Years 2014, 2025 & 2030
    • TABLE 89: Rest of Europe Recent Past, Current & Future Analysis for HER2 Breast Cancer Tests by End-user - Hospitals End-User and Diagnostic Laboratories End-User - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 90: Rest of Europe Historic Review for HER2 Breast Cancer Tests by End-user - Hospitals End-User and Diagnostic Laboratories End-User Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 91: Rest of Europe 16-Year Perspective for HER2 Breast Cancer Tests by End-user - Percentage Breakdown of Value Sales for Hospitals End-User and Diagnostic Laboratories End-User for the Years 2014, 2025 & 2030
  • ASIA-PACIFIC
    • HER2 Breast Cancer Tests Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
    • TABLE 92: Asia-Pacific Recent Past, Current & Future Analysis for HER2 Breast Cancer Tests by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 93: Asia-Pacific Historic Review for HER2 Breast Cancer Tests by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 94: Asia-Pacific 16-Year Perspective for HER2 Breast Cancer Tests by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2014, 2025 & 2030
    • TABLE 95: Asia-Pacific Recent Past, Current & Future Analysis for HER2 Breast Cancer Tests by Test Type - Immunohistochemistry Test and Fluorescence / Chromogenic In-Situ Hybridization Test - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 96: Asia-Pacific Historic Review for HER2 Breast Cancer Tests by Test Type - Immunohistochemistry Test and Fluorescence / Chromogenic In-Situ Hybridization Test Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 97: Asia-Pacific 16-Year Perspective for HER2 Breast Cancer Tests by Test Type - Percentage Breakdown of Value Sales for Immunohistochemistry Test and Fluorescence / Chromogenic In-Situ Hybridization Test for the Years 2014, 2025 & 2030
    • TABLE 98: Asia-Pacific Recent Past, Current & Future Analysis for HER2 Breast Cancer Tests by End-user - Hospitals End-User and Diagnostic Laboratories End-User - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 99: Asia-Pacific Historic Review for HER2 Breast Cancer Tests by End-user - Hospitals End-User and Diagnostic Laboratories End-User Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 100: Asia-Pacific 16-Year Perspective for HER2 Breast Cancer Tests by End-user - Percentage Breakdown of Value Sales for Hospitals End-User and Diagnostic Laboratories End-User for the Years 2014, 2025 & 2030
  • AUSTRALIA
    • HER2 Breast Cancer Tests Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
    • TABLE 101: Australia Recent Past, Current & Future Analysis for HER2 Breast Cancer Tests by Test Type - Immunohistochemistry Test and Fluorescence / Chromogenic In-Situ Hybridization Test - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 102: Australia Historic Review for HER2 Breast Cancer Tests by Test Type - Immunohistochemistry Test and Fluorescence / Chromogenic In-Situ Hybridization Test Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 103: Australia 16-Year Perspective for HER2 Breast Cancer Tests by Test Type - Percentage Breakdown of Value Sales for Immunohistochemistry Test and Fluorescence / Chromogenic In-Situ Hybridization Test for the Years 2014, 2025 & 2030
    • TABLE 104: Australia Recent Past, Current & Future Analysis for HER2 Breast Cancer Tests by End-user - Hospitals End-User and Diagnostic Laboratories End-User - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 105: Australia Historic Review for HER2 Breast Cancer Tests by End-user - Hospitals End-User and Diagnostic Laboratories End-User Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 106: Australia 16-Year Perspective for HER2 Breast Cancer Tests by End-user - Percentage Breakdown of Value Sales for Hospitals End-User and Diagnostic Laboratories End-User for the Years 2014, 2025 & 2030
  • INDIA
    • HER2 Breast Cancer Tests Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
    • TABLE 107: India Recent Past, Current & Future Analysis for HER2 Breast Cancer Tests by Test Type - Immunohistochemistry Test and Fluorescence / Chromogenic In-Situ Hybridization Test - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 108: India Historic Review for HER2 Breast Cancer Tests by Test Type - Immunohistochemistry Test and Fluorescence / Chromogenic In-Situ Hybridization Test Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 109: India 16-Year Perspective for HER2 Breast Cancer Tests by Test Type - Percentage Breakdown of Value Sales for Immunohistochemistry Test and Fluorescence / Chromogenic In-Situ Hybridization Test for the Years 2014, 2025 & 2030
    • TABLE 110: India Recent Past, Current & Future Analysis for HER2 Breast Cancer Tests by End-user - Hospitals End-User and Diagnostic Laboratories End-User - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 111: India Historic Review for HER2 Breast Cancer Tests by End-user - Hospitals End-User and Diagnostic Laboratories End-User Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 112: India 16-Year Perspective for HER2 Breast Cancer Tests by End-user - Percentage Breakdown of Value Sales for Hospitals End-User and Diagnostic Laboratories End-User for the Years 2014, 2025 & 2030
  • SOUTH KOREA
    • TABLE 113: South Korea Recent Past, Current & Future Analysis for HER2 Breast Cancer Tests by Test Type - Immunohistochemistry Test and Fluorescence / Chromogenic In-Situ Hybridization Test - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 114: South Korea Historic Review for HER2 Breast Cancer Tests by Test Type - Immunohistochemistry Test and Fluorescence / Chromogenic In-Situ Hybridization Test Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 115: South Korea 16-Year Perspective for HER2 Breast Cancer Tests by Test Type - Percentage Breakdown of Value Sales for Immunohistochemistry Test and Fluorescence / Chromogenic In-Situ Hybridization Test for the Years 2014, 2025 & 2030
    • TABLE 116: South Korea Recent Past, Current & Future Analysis for HER2 Breast Cancer Tests by End-user - Hospitals End-User and Diagnostic Laboratories End-User - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 117: South Korea Historic Review for HER2 Breast Cancer Tests by End-user - Hospitals End-User and Diagnostic Laboratories End-User Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 118: South Korea 16-Year Perspective for HER2 Breast Cancer Tests by End-user - Percentage Breakdown of Value Sales for Hospitals End-User and Diagnostic Laboratories End-User for the Years 2014, 2025 & 2030
  • REST OF ASIA-PACIFIC
    • TABLE 119: Rest of Asia-Pacific Recent Past, Current & Future Analysis for HER2 Breast Cancer Tests by Test Type - Immunohistochemistry Test and Fluorescence / Chromogenic In-Situ Hybridization Test - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 120: Rest of Asia-Pacific Historic Review for HER2 Breast Cancer Tests by Test Type - Immunohistochemistry Test and Fluorescence / Chromogenic In-Situ Hybridization Test Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 121: Rest of Asia-Pacific 16-Year Perspective for HER2 Breast Cancer Tests by Test Type - Percentage Breakdown of Value Sales for Immunohistochemistry Test and Fluorescence / Chromogenic In-Situ Hybridization Test for the Years 2014, 2025 & 2030
    • TABLE 122: Rest of Asia-Pacific Recent Past, Current & Future Analysis for HER2 Breast Cancer Tests by End-user - Hospitals End-User and Diagnostic Laboratories End-User - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 123: Rest of Asia-Pacific Historic Review for HER2 Breast Cancer Tests by End-user - Hospitals End-User and Diagnostic Laboratories End-User Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 124: Rest of Asia-Pacific 16-Year Perspective for HER2 Breast Cancer Tests by End-user - Percentage Breakdown of Value Sales for Hospitals End-User and Diagnostic Laboratories End-User for the Years 2014, 2025 & 2030
  • LATIN AMERICA
    • HER2 Breast Cancer Tests Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
    • TABLE 125: Latin America Recent Past, Current & Future Analysis for HER2 Breast Cancer Tests by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 126: Latin America Historic Review for HER2 Breast Cancer Tests by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 127: Latin America 16-Year Perspective for HER2 Breast Cancer Tests by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2014, 2025 & 2030
    • TABLE 128: Latin America Recent Past, Current & Future Analysis for HER2 Breast Cancer Tests by Test Type - Immunohistochemistry Test and Fluorescence / Chromogenic In-Situ Hybridization Test - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 129: Latin America Historic Review for HER2 Breast Cancer Tests by Test Type - Immunohistochemistry Test and Fluorescence / Chromogenic In-Situ Hybridization Test Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 130: Latin America 16-Year Perspective for HER2 Breast Cancer Tests by Test Type - Percentage Breakdown of Value Sales for Immunohistochemistry Test and Fluorescence / Chromogenic In-Situ Hybridization Test for the Years 2014, 2025 & 2030
    • TABLE 131: Latin America Recent Past, Current & Future Analysis for HER2 Breast Cancer Tests by End-user - Hospitals End-User and Diagnostic Laboratories End-User - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 132: Latin America Historic Review for HER2 Breast Cancer Tests by End-user - Hospitals End-User and Diagnostic Laboratories End-User Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 133: Latin America 16-Year Perspective for HER2 Breast Cancer Tests by End-user - Percentage Breakdown of Value Sales for Hospitals End-User and Diagnostic Laboratories End-User for the Years 2014, 2025 & 2030
  • ARGENTINA
    • TABLE 134: Argentina Recent Past, Current & Future Analysis for HER2 Breast Cancer Tests by Test Type - Immunohistochemistry Test and Fluorescence / Chromogenic In-Situ Hybridization Test - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 135: Argentina Historic Review for HER2 Breast Cancer Tests by Test Type - Immunohistochemistry Test and Fluorescence / Chromogenic In-Situ Hybridization Test Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 136: Argentina 16-Year Perspective for HER2 Breast Cancer Tests by Test Type - Percentage Breakdown of Value Sales for Immunohistochemistry Test and Fluorescence / Chromogenic In-Situ Hybridization Test for the Years 2014, 2025 & 2030
    • TABLE 137: Argentina Recent Past, Current & Future Analysis for HER2 Breast Cancer Tests by End-user - Hospitals End-User and Diagnostic Laboratories End-User - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 138: Argentina Historic Review for HER2 Breast Cancer Tests by End-user - Hospitals End-User and Diagnostic Laboratories End-User Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 139: Argentina 16-Year Perspective for HER2 Breast Cancer Tests by End-user - Percentage Breakdown of Value Sales for Hospitals End-User and Diagnostic Laboratories End-User for the Years 2014, 2025 & 2030
  • BRAZIL
    • TABLE 140: Brazil Recent Past, Current & Future Analysis for HER2 Breast Cancer Tests by Test Type - Immunohistochemistry Test and Fluorescence / Chromogenic In-Situ Hybridization Test - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 141: Brazil Historic Review for HER2 Breast Cancer Tests by Test Type - Immunohistochemistry Test and Fluorescence / Chromogenic In-Situ Hybridization Test Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 142: Brazil 16-Year Perspective for HER2 Breast Cancer Tests by Test Type - Percentage Breakdown of Value Sales for Immunohistochemistry Test and Fluorescence / Chromogenic In-Situ Hybridization Test for the Years 2014, 2025 & 2030
    • TABLE 143: Brazil Recent Past, Current & Future Analysis for HER2 Breast Cancer Tests by End-user - Hospitals End-User and Diagnostic Laboratories End-User - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 144: Brazil Historic Review for HER2 Breast Cancer Tests by End-user - Hospitals End-User and Diagnostic Laboratories End-User Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 145: Brazil 16-Year Perspective for HER2 Breast Cancer Tests by End-user - Percentage Breakdown of Value Sales for Hospitals End-User and Diagnostic Laboratories End-User for the Years 2014, 2025 & 2030
  • MEXICO
    • TABLE 146: Mexico Recent Past, Current & Future Analysis for HER2 Breast Cancer Tests by Test Type - Immunohistochemistry Test and Fluorescence / Chromogenic In-Situ Hybridization Test - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 147: Mexico Historic Review for HER2 Breast Cancer Tests by Test Type - Immunohistochemistry Test and Fluorescence / Chromogenic In-Situ Hybridization Test Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 148: Mexico 16-Year Perspective for HER2 Breast Cancer Tests by Test Type - Percentage Breakdown of Value Sales for Immunohistochemistry Test and Fluorescence / Chromogenic In-Situ Hybridization Test for the Years 2014, 2025 & 2030
    • TABLE 149: Mexico Recent Past, Current & Future Analysis for HER2 Breast Cancer Tests by End-user - Hospitals End-User and Diagnostic Laboratories End-User - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 150: Mexico Historic Review for HER2 Breast Cancer Tests by End-user - Hospitals End-User and Diagnostic Laboratories End-User Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 151: Mexico 16-Year Perspective for HER2 Breast Cancer Tests by End-user - Percentage Breakdown of Value Sales for Hospitals End-User and Diagnostic Laboratories End-User for the Years 2014, 2025 & 2030
  • REST OF LATIN AMERICA
    • TABLE 152: Rest of Latin America Recent Past, Current & Future Analysis for HER2 Breast Cancer Tests by Test Type - Immunohistochemistry Test and Fluorescence / Chromogenic In-Situ Hybridization Test - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 153: Rest of Latin America Historic Review for HER2 Breast Cancer Tests by Test Type - Immunohistochemistry Test and Fluorescence / Chromogenic In-Situ Hybridization Test Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 154: Rest of Latin America 16-Year Perspective for HER2 Breast Cancer Tests by Test Type - Percentage Breakdown of Value Sales for Immunohistochemistry Test and Fluorescence / Chromogenic In-Situ Hybridization Test for the Years 2014, 2025 & 2030
    • TABLE 155: Rest of Latin America Recent Past, Current & Future Analysis for HER2 Breast Cancer Tests by End-user - Hospitals End-User and Diagnostic Laboratories End-User - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 156: Rest of Latin America Historic Review for HER2 Breast Cancer Tests by End-user - Hospitals End-User and Diagnostic Laboratories End-User Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 157: Rest of Latin America 16-Year Perspective for HER2 Breast Cancer Tests by End-user - Percentage Breakdown of Value Sales for Hospitals End-User and Diagnostic Laboratories End-User for the Years 2014, 2025 & 2030
  • MIDDLE EAST
    • HER2 Breast Cancer Tests Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
    • TABLE 158: Middle East Recent Past, Current & Future Analysis for HER2 Breast Cancer Tests by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 159: Middle East Historic Review for HER2 Breast Cancer Tests by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 160: Middle East 16-Year Perspective for HER2 Breast Cancer Tests by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2014, 2025 & 2030
    • TABLE 161: Middle East Recent Past, Current & Future Analysis for HER2 Breast Cancer Tests by Test Type - Immunohistochemistry Test and Fluorescence / Chromogenic In-Situ Hybridization Test - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 162: Middle East Historic Review for HER2 Breast Cancer Tests by Test Type - Immunohistochemistry Test and Fluorescence / Chromogenic In-Situ Hybridization Test Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 163: Middle East 16-Year Perspective for HER2 Breast Cancer Tests by Test Type - Percentage Breakdown of Value Sales for Immunohistochemistry Test and Fluorescence / Chromogenic In-Situ Hybridization Test for the Years 2014, 2025 & 2030
    • TABLE 164: Middle East Recent Past, Current & Future Analysis for HER2 Breast Cancer Tests by End-user - Hospitals End-User and Diagnostic Laboratories End-User - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 165: Middle East Historic Review for HER2 Breast Cancer Tests by End-user - Hospitals End-User and Diagnostic Laboratories End-User Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 166: Middle East 16-Year Perspective for HER2 Breast Cancer Tests by End-user - Percentage Breakdown of Value Sales for Hospitals End-User and Diagnostic Laboratories End-User for the Years 2014, 2025 & 2030
  • IRAN
    • TABLE 167: Iran Recent Past, Current & Future Analysis for HER2 Breast Cancer Tests by Test Type - Immunohistochemistry Test and Fluorescence / Chromogenic In-Situ Hybridization Test - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 168: Iran Historic Review for HER2 Breast Cancer Tests by Test Type - Immunohistochemistry Test and Fluorescence / Chromogenic In-Situ Hybridization Test Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 169: Iran 16-Year Perspective for HER2 Breast Cancer Tests by Test Type - Percentage Breakdown of Value Sales for Immunohistochemistry Test and Fluorescence / Chromogenic In-Situ Hybridization Test for the Years 2014, 2025 & 2030
    • TABLE 170: Iran Recent Past, Current & Future Analysis for HER2 Breast Cancer Tests by End-user - Hospitals End-User and Diagnostic Laboratories End-User - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 171: Iran Historic Review for HER2 Breast Cancer Tests by End-user - Hospitals End-User and Diagnostic Laboratories End-User Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 172: Iran 16-Year Perspective for HER2 Breast Cancer Tests by End-user - Percentage Breakdown of Value Sales for Hospitals End-User and Diagnostic Laboratories End-User for the Years 2014, 2025 & 2030
  • ISRAEL
    • TABLE 173: Israel Recent Past, Current & Future Analysis for HER2 Breast Cancer Tests by Test Type - Immunohistochemistry Test and Fluorescence / Chromogenic In-Situ Hybridization Test - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 174: Israel Historic Review for HER2 Breast Cancer Tests by Test Type - Immunohistochemistry Test and Fluorescence / Chromogenic In-Situ Hybridization Test Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 175: Israel 16-Year Perspective for HER2 Breast Cancer Tests by Test Type - Percentage Breakdown of Value Sales for Immunohistochemistry Test and Fluorescence / Chromogenic In-Situ Hybridization Test for the Years 2014, 2025 & 2030
    • TABLE 176: Israel Recent Past, Current & Future Analysis for HER2 Breast Cancer Tests by End-user - Hospitals End-User and Diagnostic Laboratories End-User - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 177: Israel Historic Review for HER2 Breast Cancer Tests by End-user - Hospitals End-User and Diagnostic Laboratories End-User Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 178: Israel 16-Year Perspective for HER2 Breast Cancer Tests by End-user - Percentage Breakdown of Value Sales for Hospitals End-User and Diagnostic Laboratories End-User for the Years 2014, 2025 & 2030
  • SAUDI ARABIA
    • TABLE 179: Saudi Arabia Recent Past, Current & Future Analysis for HER2 Breast Cancer Tests by Test Type - Immunohistochemistry Test and Fluorescence / Chromogenic In-Situ Hybridization Test - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 180: Saudi Arabia Historic Review for HER2 Breast Cancer Tests by Test Type - Immunohistochemistry Test and Fluorescence / Chromogenic In-Situ Hybridization Test Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 181: Saudi Arabia 16-Year Perspective for HER2 Breast Cancer Tests by Test Type - Percentage Breakdown of Value Sales for Immunohistochemistry Test and Fluorescence / Chromogenic In-Situ Hybridization Test for the Years 2014, 2025 & 2030
    • TABLE 182: Saudi Arabia Recent Past, Current & Future Analysis for HER2 Breast Cancer Tests by End-user - Hospitals End-User and Diagnostic Laboratories End-User - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 183: Saudi Arabia Historic Review for HER2 Breast Cancer Tests by End-user - Hospitals End-User and Diagnostic Laboratories End-User Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 184: Saudi Arabia 16-Year Perspective for HER2 Breast Cancer Tests by End-user - Percentage Breakdown of Value Sales for Hospitals End-User and Diagnostic Laboratories End-User for the Years 2014, 2025 & 2030
  • UNITED ARAB EMIRATES
    • TABLE 185: UAE Recent Past, Current & Future Analysis for HER2 Breast Cancer Tests by Test Type - Immunohistochemistry Test and Fluorescence / Chromogenic In-Situ Hybridization Test - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 186: UAE Historic Review for HER2 Breast Cancer Tests by Test Type - Immunohistochemistry Test and Fluorescence / Chromogenic In-Situ Hybridization Test Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 187: UAE 16-Year Perspective for HER2 Breast Cancer Tests by Test Type - Percentage Breakdown of Value Sales for Immunohistochemistry Test and Fluorescence / Chromogenic In-Situ Hybridization Test for the Years 2014, 2025 & 2030
    • TABLE 188: UAE Recent Past, Current & Future Analysis for HER2 Breast Cancer Tests by End-user - Hospitals End-User and Diagnostic Laboratories End-User - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 189: UAE Historic Review for HER2 Breast Cancer Tests by End-user - Hospitals End-User and Diagnostic Laboratories End-User Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 190: UAE 16-Year Perspective for HER2 Breast Cancer Tests by End-user - Percentage Breakdown of Value Sales for Hospitals End-User and Diagnostic Laboratories End-User for the Years 2014, 2025 & 2030
  • REST OF MIDDLE EAST
    • TABLE 191: Rest of Middle East Recent Past, Current & Future Analysis for HER2 Breast Cancer Tests by Test Type - Immunohistochemistry Test and Fluorescence / Chromogenic In-Situ Hybridization Test - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 192: Rest of Middle East Historic Review for HER2 Breast Cancer Tests by Test Type - Immunohistochemistry Test and Fluorescence / Chromogenic In-Situ Hybridization Test Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 193: Rest of Middle East 16-Year Perspective for HER2 Breast Cancer Tests by Test Type - Percentage Breakdown of Value Sales for Immunohistochemistry Test and Fluorescence / Chromogenic In-Situ Hybridization Test for the Years 2014, 2025 & 2030
    • TABLE 194: Rest of Middle East Recent Past, Current & Future Analysis for HER2 Breast Cancer Tests by End-user - Hospitals End-User and Diagnostic Laboratories End-User - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 195: Rest of Middle East Historic Review for HER2 Breast Cancer Tests by End-user - Hospitals End-User and Diagnostic Laboratories End-User Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 196: Rest of Middle East 16-Year Perspective for HER2 Breast Cancer Tests by End-user - Percentage Breakdown of Value Sales for Hospitals End-User and Diagnostic Laboratories End-User for the Years 2014, 2025 & 2030
  • AFRICA
    • HER2 Breast Cancer Tests Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
    • TABLE 197: Africa Recent Past, Current & Future Analysis for HER2 Breast Cancer Tests by Test Type - Immunohistochemistry Test and Fluorescence / Chromogenic In-Situ Hybridization Test - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 198: Africa Historic Review for HER2 Breast Cancer Tests by Test Type - Immunohistochemistry Test and Fluorescence / Chromogenic In-Situ Hybridization Test Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 199: Africa 16-Year Perspective for HER2 Breast Cancer Tests by Test Type - Percentage Breakdown of Value Sales for Immunohistochemistry Test and Fluorescence / Chromogenic In-Situ Hybridization Test for the Years 2014, 2025 & 2030
    • TABLE 200: Africa Recent Past, Current & Future Analysis for HER2 Breast Cancer Tests by End-user - Hospitals End-User and Diagnostic Laboratories End-User - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 201: Africa Historic Review for HER2 Breast Cancer Tests by End-user - Hospitals End-User and Diagnostic Laboratories End-User Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 202: Africa 16-Year Perspective for HER2 Breast Cancer Tests by End-user - Percentage Breakdown of Value Sales for Hospitals End-User and Diagnostic Laboratories End-User for the Years 2014, 2025 & 2030

IV. COMPETITION

샘플 요청 목록
0 건의 상품을 선택 중
목록 보기
전체삭제